Miastenia grave autoimune
aspectos clínicos e experimentais
DOI:
https://doi.org/10.34024/rnc.2005.v13.10352Palavras-chave:
Miastenia Gravis, Fisioterapia, Atividade MotoraResumo
A Miastenia Grave (MG) é caracterizada por uma alteração na transmissão nervo músculo, decorrente da deficiência, bloqueio e destruição de receptores de acetilcolina na junção neuromuscular. A presente revisão tem o objetivo de trazer informações atuais sobre a MG, abrangendo os seguintes aspectos: histórico; fisiopatologia; procedimentos diagnósticos; classificação e tratamento da doença. Além disso, revisamos os principais modelos experimentais que mimetizam as manifestações clínicas observadas na MG humana.
Downloads
Métricas
Referências
2. Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong. Myologi. 2ºed. [S.L]: Mc Graw Hill; 1994, p 1769-1797.
3. Gomes MM. Doenças. In: Gomes MM. Marcos históricos da neurologia. Rio de Janeiro: Científica Nacional; 1997, p 79-114.
4. Rowland LP. Doença da transmissão química na sinapse neuromuscular: Miastenia grave. In: Kandel ER, Schwartz JH, Jessel TM. Princípios da neurociência. Traduzido por: Andréa da Silva Torrão. 4a ed. São Paulo: Manole; 2003, p 298-308.
5. Simpson JA. Myasthenia gravis: A new hypothesis. Scot Med J 1960; 5:419-422.
6. Blalock, A, Masson, MF, Morgan, Hj, Riven, SS. Myasthenia gravis and tumors of the thymic region: Report of case in which the tumor was removed. Ann. Surg 1939; 110:544-561.
7. Harvey AM, Lilienthal JL Jr., Talbot SA. Observation on the nature of myasthenia gravis the phenomena of facilitation and depression of neuromuscular transmission. Bull Jhons Hopkins Hosp. 1941; 69:547-565
8. Chang CC, Lee CY. Electrophysiological study of neuromuscular blocking action of cobra neurotoxin. Br J Pharm Chemother 1966; 28:172-181.
9. Frambrough DM, Drachamn DB. Neuromuscular junction in myasthenia gravis: Decreased acetylholine receptors. Sciene 1973; 182:293-295.
10. Phillips II LH. The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003; 998:407-412.
11. Penn AS, ROWLAND LP. Myasthenia gravis. In: ROWLAND LP. Merritt’s neurology. 10ºed Philadelphia: Lippincott Willians e Wilkinkns; 2000. p.721-726
12. Drachman DB. Myasthenia gravis and other diseases of the neuromuscular junction. In: Fauci AS et al. Harrison’s principles of internal medicine. 15ºed. [S.L]: Mc Graw Hill; 2001. p.2515-2520.
13. Mora A, Cortès C, Mateo EM, Pla M, Cabarrocas E. Miastenia grave. Rev Esp Anestesiol. Reanim 1990; 37:284-290.
14. Zuleta JJ, Fanbug BL. Respiratory dysfunction in myasthenia gravis. Clinics in Chest Medicine 1994; 15:683-671.
15. Cambier J, Masson M, Dehen H. Patologia muscular. In: Cambier J, Masson M, Dehen H. Manual de neurologia. Traduzido por: Sergio Augusto Pereira Noris. Rio de Janeiro: Masson do Brasil; 1980. p.518-536.
16. Jacobs-Burleigh A. Synapse e transmissão sináptica. In: Ekman-Lundy L. Neurociência: Fundamentos para a reabilitação. Traduzido por: Charles A Esbérard. Rio de Janeiro: Granabara Koogan; 2000. p. 33-42.
17. Chaudhuri A, Obehan P. Fatigue in neurological disorders. The Lancet 2004; 363:978-987. 2004.
18. Osserman KE, Genkis G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. MT Sinai J Med 1971; 38:497-537.
19. Arora NS, Gal TJ. Cough dynamics during progressive expiratory muscle weakness in healthy curarized subjects. J Appl Physiol 1981; 51:494.
20. Bennett JC, Plum F. Neurologia. In: Bennett JC, Plum F. Neurologia. Cecil tratado de medicina interna. Traduzido por: Maria F Azevedo. 20ºed. Rio de Janeiro: Guanabara Koogan; 1997. p.2394-2397.
21. Compston DA, Vicent A, Newsom-Davis J et al. Clinical, pathological, HLA antigen and immunological evidence for heterogeneity in myasthenia gravis. Brain 1980; 103:579.
22. Limburg PC, Hummel-Tapel E et al. Antiacetylcholine receptor antibodien in myasthenia gravis. Part I. Relation to clinical parameters in 250 patients. J Neurol Sci 1983; 58:357-362.
23. Calcaterra TC, Steern F. The otolatingologist’s role in myasthenia gravis. Am Acad Ophthalmol Otolaryngol 1972; 76:308.
24. Oliveira ABS, Gabbai AA. Doenças neuromusculares. In: Prado FC, Ramos JA, Valle JR. Atualização terapêutica: Manual prático de diagnóstico e tratamento. 20ºed. São Paulo: Artes Médicas; 2001. p.815-826.
25. Lindstrom J. Experimental autoimmune myasthenia gravis. J Nerol Neuros Psych 1980; 43:568-576.
26. Gronseth GS, Barohn RJ. Pratice parameter: Tymectomy of autoimmune myasthenia gravis (an evidence-based review). Neurology 2000;55:7-15.
27. Werneck LC, Cunha FMB, Scola RL. Myasthenia gravis: a retrospective study comparing tymectomy to conservative treatment. Acta Neurol Scand 2000; 101:41-46.
28. Kennan SP et al. Ventilatory muscle strength and endurance in myasthenia gravis. Eur Respir J 1995; 8:1130-1135.
29. Weiner P et al. Respiratory muscle training in patients with moderate to severe myasthenia gravis. Can J Neurol Sci 1998; 25:236-241.
30. Lena-Eva L, Lindberg C, Andersen O. Physical training effects in myasthenia gravis. Arch Phys Med Rehabil 1993; 74:1178-1180.
31. Nachmanson, D. Chemical and molecular basis of nerve activity. New York: Academic Press, 1959
32. Kiefer H, Lindstrom J, Lennox ES, Singer SJ. Photo-affinity labeling of specific acetylcoline binding sites on membranes. Proc Natl Acad Sci 1970; 67:1688-1694.
33. Lindstrom JM. Nicotinic acetylcholine receptors of muscle and nerves: Comparison of their structures, functional roles and vulnerability to pathology. Ann NY Acad Sci 2003; 998:41-52.
34. Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcholine receptors and the cousis. Neuron 1995; 15:1231-1244.
35. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973; 180:871-873.
36. Lennon VA, Lindstrom J, Seybold ME. Experimental autoimune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975; 141:365-1375.
37. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. J Clin Immunol Immunopath 1977; 7:36-43.
38. Baggi F et al. Immunization with rat, but not Torpedo-derived 97-116 peptide of the Ach alfa-subunit induces experi
mental myasthenia gravis in Lewis rat. Ann NY Acad Sci 2003; 998:391-394.
39. Baggi F et al. Breakdown of tolerance to a self-peptide of acetylcholine receptor alfa-subunit induces experimental myasthenia gravis in rats. J Immunol 2004; 172:2697-2703.
40. Guo-Bao X, Hans L. Rat model as tool to develop new immunotherapies. Immunol Rev 2001; 184:117-128.
41. Lindstrom JM, Einarson B, Lennon VA, Seybold ME. Pathological mechanisms in EAMG I: Imunogenicity of syngenic muscle acetylcholine receptor and quantitative extraction of receptor and anti-body receptor complexes for muscles of rats with experimental autoimmune myasthenia gravis. J Exp Med 1976; 144:726-738.
42. Lindstrom JM, Engel AG, Seybold ME, Lennon VA, Lambert EH. Pathological mechanisms in EAMG II: Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976; 144:739-753.
43. Kandel ER, Siegelbaum AS. Sinalização na sinapse neuromuscular: transmissão por ativação direta. In: kandel ER et al. Princípios da neurociência. 4ºed. Traduzido por: Andréa S Torrão. São Paulo: Manole; 2003. p.187-205.
44. Engel AG, Lindstrom JM, Lambert EH, Lennon VA. Ultra structural localization of the acetylcholine receptor in myasthenia gravis and its experimental autoimmune model. Neurology 1977; 27:307-315.
45. Maiti PK, Feferman T, Im SH, Soroujon MC, Fuchs S. Immunosupression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol 2004; 152: 112-120.
46. Im SH, Barchan D, Fuchs S, Souroujon MC. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J Neuroimmunol 2000; 116:161-168.
47. Vang ZY, Quião J, Hans L. Supression fo experimental autoimmune myasthenia gravis by oral administração of acetylcholine receptor. J Neuroimmunol 1993; 44:209-214.
48. Silva S, Mclutosh K, Blum JE, Order S, Mellits D, Drachamn DB. Total lymphoid irradiation and antigen-specific tolerance: future therapy for experimental autoimmune myasthenia gravis. J Neuroimmunol 1990; 29:93-103.
49. Takamori M, Mori M, Kassai M. Experimental autoimmune myasthenia gravis and cholinergic ionnphore: An eletrophisiologic stud. Neurology 1979; 29-945-950.
Downloads
Publicado
Como Citar
Edição
Seção
##plugins.generic.dates.published## 2005-09-30